
Stephen Palmer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5873738/publications.pdf Version: 2024-02-01



STEDHEN DAIMED

#	Article	IF	CITATIONS
1	Estimating and Extrapolating Survival Using a State-Transition Modeling Approach: A Practical Application in Multiple Myeloma. Value in Health, 2022, 25, 595-604.	0.1	2
2	Exploring Heterogeneity in Histology-Independent Technologies and the Implications for Cost-Effectiveness. Medical Decision Making, 2021, 41, 165-178.	1.2	8
3	Classifying information-sharing methods. BMC Medical Research Methodology, 2021, 21, 107.	1.4	6
4	Cost-effectiveness of point-of-care creatinine testing to assess kidney function prior to contrast-enhanced computed tomography imaging. European Journal of Radiology, 2021, 142, 109872.	1.2	0
5	Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. Health Technology Assessment, 2021, 25, 1-228.	1.3	7
6	How should we assess the clinical and cost effectiveness of histology independent cancer drugs?. BMJ, The, 2020, 368, l6435.	3.0	14
7	HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. European Journal of Health Economics, 2020, 21, 1421-1437.	1.4	38
8	Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?. Value in Health, 2020, 23, 1613-1621.	0.1	57
9	After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?. Pharmacoeconomics, 2020, 38, 247-257.	1.7	13
10	Economic evaluations in migraine: systematic literature review and a novel approach. Journal of Medical Economics, 2020, 23, 864-876.	1.0	9
11	Interventions based on early intensive applied behaviour analysis for autistic children: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2020, 24, 1-306.	1.3	31
12	Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation. Health Technology Assessment, 2020, 24, 1-248.	1.3	12
13	Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 131-139.	1.7	7
14	Time Horizons in Cost Analyses. JAMA - Journal of the American Medical Association, 2019, 322, 582.	3.8	3
15	Migraine day frequency in migraine prevention: longitudinal modelling approaches. BMC Medical Research Methodology, 2019, 19, 20.	1.4	8
16	The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 1081-1091.	1.7	5
17	Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia. Advances in Therapy, 2019, 36, 950-961.	1.3	19
18	Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology. Pharmacoeconomics, 2019, 37, 727-737.	1.7	4

STEPHEN PALMER

#	Article	IF	CITATIONS
19	Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. Journal of Medical Economics, 2018, 21, 666-675.	1.0	36
20	Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal. Medical Decision Making, 2018, 38, 200-211.	1.2	196
21	Indirect treatment comparison of blinatumomab versus inotuzumab ozogamicin for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy Journal of Clinical Oncology, 2018, 36, e19000-e19000.	0.8	1
22	High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation. Health Technology Assessment, 2018, 22, 1-172.	1.3	16
23	Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: systematic reviews and economic evaluation. Health Technology Assessment, 2018, 22, 1-260.	1.3	6
24	Estimating Long-Term Survival in a Cohort of Allogeneic Hematopoietic Stem Cell Transplant Patients. Blood, 2018, 132, 3556-3556.	0.6	0
25	How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral Anticoagulants. Medical Decision Making, 2017, 37, 148-161.	1.2	18
26	Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs. Health Economics (United Kingdom), 2017, 26, 109-123.	0.8	52
27	How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis. Pharmacoeconomics, 2017, 35, 767-776.	1.7	14
28	Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison. Advances in Therapy, 2017, 34, 495-512.	1.3	5
29	The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technology Assessment, 2017, 21, 1-204.	1.3	95
30	Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technology Assessment, 2017, 21, 1-326.	1.3	21
31	Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. Health Technology Assessment, 2017, 21, 1-244.	1.3	16
32	Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER). European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 125-140.	1.8	49
33	The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence. Pharmacoeconomics, 2016, 34, 1101-1110.	1.7	2
34	A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions. Value in Health, 2016, 19, 885-891.	0.1	38
35	The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence. Pharmacoeconomics, 2016, 34, 901-912.	1.7	7
36	Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?. Value in Health, 2016, 19, 138-144.	0.1	24

STEPHEN PALMER

#	Article	IF	CITATIONS
37	Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma. Advances in Therapy, 2016, 33, 643-657.	1.3	10
38	Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence. Pharmacoeconomics, 2016, 34, 587-596.	1.7	3
39	Using electronic health records to predict costs and outcomes in stable coronary artery disease. Heart, 2016, 102, 755-762.	1.2	26
40	Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technology Assessment, 2016, 20, 1-334.	1.3	62
41	The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial. Health Technology Assessment, 2016, 20, 1-64.	1.3	31
42	Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required. Value in Health, 2015, 18, 865-875.	0.1	17
43	Accounting for Heterogeneity in Relative Treatment Effects for Use in Cost-Effectiveness Models and Value-of-Information Analyses. Medical Decision Making, 2015, 35, 608-621.	1.2	16
44	Screening for psychological and mental health difficulties in young people who offend: a systematic review and decision model. Health Technology Assessment, 2015, 19, 1-128.	1.3	5
45	A randomised controlled trial of computerised cognitive behaviour therapy for the treatment of depression in primary care: the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial. Health Technology Assessment, 2015, 19, 1-174.	1.3	55
46	Clinical effectiveness and cost-effectiveness of parenting interventions for children with severe attachment problems: a systematic review and meta-analysis. Health Technology Assessment, 2015, 19, 1-348.	1.3	32
47	Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis. Health Technology Assessment, 2015, 19, 1-220.	1.3	26
48	Optimizing the Position and Use of Omalizumab for Severe Persistent Allergic Asthma Using Cost-Effectiveness Analysis. Value in Health, 2014, 17, 772-782.	0.1	36
49	The added clinical and economic value of diagnostic testing for epilepsy surgery. Epilepsy Research, 2014, 108, 775-781.	0.8	16
50	Dronedarone per il trattamento della fibrillazione atriale. Pharmacoeconomics Italian Research Articles, 2013, 15, 91-100.	0.2	0
51	The Cost-Effectiveness of Cognitive Behavior Therapy for Borderline Personality Disorder: Results from the BOSCOT Trial. Journal of Personality Disorders, 2006, 20, 466-481.	0.8	60
52	Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?. International Journal of Cardiology, 2005, 100, 229-240.	0.8	39
53	Common Errors and Controversies in Pharmacoeconomic Analyses. Pharmacoeconomics, 1998, 13, 659-666.	1.7	29